Study wrapper · #588
Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.
Editor's note
In a rat study using standard pain tests (tail-flick and hot-plate), researchers reported that the ghrelin-receptor agonist hexarelin, given alongside morphine, reduced the development of tolerance to morphine's pain-relieving effect and enhanced morphine's antinociception, while a ghrelin-receptor antagonist had no significant effect. The finding points to GHS-receptor signaling as a modulator of opioid analgesia in rodents. This is an early behavioral-pharmacology signal in a single species with a specific dosing regimen; it does not establish clinical relevance, safety, or an effect in humans, and pain-behavior models translate imperfectly. These are preclinical findings; human data are needed before any clinical conclusions can be drawn. Note hexarelin's cardiovascular and metabolic literature is far larger than its opioid-interaction literature, so this remains an isolated result.
Plain-language abstract
Scientists tested whether hexarelin, a lab-made peptide that activates the ghrelin receptor, changes how well morphine relieves pain in rats. Animals were made tolerant to morphine over three days, then tested with heat-based pain tests. Giving hexalin together with morphine lessened the loss of pain relief that comes with tolerance and actually increased morphine's pain-relieving effect. A drug that blocks the ghrelin receptor did not have this benefit. The authors conclude that activating the ghrelin receptor with hexarelin can strengthen morphine's effect and slow tolerance in rats. The abstract reports no adverse events. This is a preclinical animal study; whether any of this applies to people is unknown and would require human research.